Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:AMT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$8.89+2.8%$9.92$2.09▼$14.84$477.66M0.086.03 million shs11.12 million shsAMTAmerican Tower$197.40+1.7%$196.36$154.58▼$219.10$90.52B0.682.34 million shs2.49 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+2.77%-4.82%-21.47%-23.49%+101.13%AMTAmerican Tower+1.70%+1.42%+5.16%-9.11%+2.35%Trending Stocks Sent To You In Real Time (Ad)Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next AlertMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.33 of 5 stars3.42.00.00.02.21.70.0AMTAmerican Tower4.8749 of 5 stars2.54.04.23.13.32.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.75Moderate Buy$15.7577.17% UpsideAMTAmerican Tower2.91Moderate Buy$217.5510.21% UpsideCurrent Analyst RatingsLatest ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $234.002/28/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$235.00 ➝ $228.002/28/2024AMTAmerican TowerJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$236.00 ➝ $230.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.001/24/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$229.00 ➝ $224.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$4.41M108.31N/AN/A$3.77 per share2.36AMTAmerican Tower$11.14B8.26$10.00 per share19.74$23.30 per share8.47Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$84.71M-$1.54N/AN/AN/AN/A-46.81%-42.23%N/AAMTAmerican Tower$1.48B$3.1862.0818.731.3513.31%12.80%2.24%4/24/2024 (Estimated)Latest ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/202412/31/2023AMTAmerican Tower$2.10$0.94-$1.16$0.18$2.74 billion$2.79 billion DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.483.28%+12.50%203.77%12 YearsLatest ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A12.8912.89AMTAmerican Tower3.290.690.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5253.73 million51.53 millionOptionableAMTAmerican Tower5,643466.35 million465.23 millionOptionableADR, AMT, and ALT HeadlinesSourceHeadlineAmerican Tower (AMT) Outperforms Broader Market: What You Need to Knowzacks.com - March 27 at 7:21 PMAmerican Tower Stock: Capitalize On The Misunderstood Dividend Cutseekingalpha.com - March 26 at 1:30 PMBuy American Tower's Recent Dip As The Management Delivers Sustainable Growth & Income (Rating Upgrade)seekingalpha.com - March 26 at 10:00 AMRaymond James Financial Services Advisors Inc. Sells 14,312 Shares of American Tower Co. (NYSE:AMT)marketbeat.com - March 26 at 6:34 AMWhy Investors Need to Take Advantage of These 2 Finance Stocks Nowzacks.com - March 25 at 9:51 AMKingswood Wealth Advisors LLC Purchases 6,472 Shares of American Tower Co. (NYSE:AMT)marketbeat.com - March 25 at 8:31 AMAmerican Tower Co. (NYSE:AMT) Given Consensus Rating of "Moderate Buy" by Analystsamericanbankingnews.com - March 25 at 1:34 AMAmerican Tower: Don't Be Fooled By The Dividend Cutseekingalpha.com - March 25 at 12:20 AMRaymond James & Associates Has $267.73 Million Stock Holdings in American Tower Co. (NYSE:AMT)marketbeat.com - March 24 at 8:09 PMBorder to Coast Pensions Partnership Ltd Has $91.40 Million Stake in American Tower Co. (NYSE:AMT)marketbeat.com - March 23 at 7:22 PMAmerican Tower (AMT) Stock Dips While Market Gains: Key Factszacks.com - March 21 at 7:21 PMAmerican Tower Co. (NYSE:AMT) Stock Position Trimmed by LVM Capital Management Ltd. MImarketbeat.com - March 21 at 4:43 PMAmerican Tower (AMT) Upgraded to Buy: Here's What You Should Knowzacks.com - March 21 at 1:01 PMWall Street Bulls Look Optimistic About American Tower (AMT): Should You Buy?zacks.com - March 21 at 10:31 AM7 of the Best Residential REITs to Buy Todaymsn.com - March 20 at 5:06 PMDiversified Trust Co Sells 10,428 Shares of American Tower Co. (NYSE:AMT)marketbeat.com - March 20 at 5:35 AMAEGON ASSET MANAGEMENT UK Plc Purchases Shares of 331,064 American Tower Co. (NYSE:AMT)marketbeat.com - March 19 at 8:39 PMGilman Hill Asset Management LLC Invests $5.88 Million in American Tower Co. (NYSE:AMT)marketbeat.com - March 18 at 11:38 PMAMT Apr 2024 195.000 putfinance.yahoo.com - March 18 at 12:16 AMSarasin & Partners LLP Purchases 314,970 Shares of American Tower Co. (NYSE:AMT)marketbeat.com - March 18 at 12:01 AMInsidious Inflationseekingalpha.com - March 17 at 9:14 AMRLTY: 9% Income, Attractive Discount And Benefit From A Real Estate Turnaroundseekingalpha.com - March 17 at 9:14 AMAmerican Tower Co. (NYSE:AMT) Short Interest Updatemarketbeat.com - March 16 at 11:03 PM12,965 Shares in American Tower Co. (NYSE:AMT) Acquired by Jackson Square Capital LLCmarketbeat.com - March 16 at 2:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.